Results 121 to 130 of about 15,392,732 (265)

Mucosal immunity and vaccine development. [PDF]

Signal Transduct Target Ther
Hong W, Alu A, Zhang Z, Zhang Y, He X, Xu L, Li M, He W, Wang J.   +8 more
europepmc   +1 more source

Chronic HBV Infection Disrupts CCL5‐Secreting cNK Cells and Attenuates Liver Accumulation and Activation of DCs and HBV‐Specific T Cells

Advanced Science, EarlyView.
ADORA2A activation suppresses NFκB‐dependent CCL5 production in cNK cells during chronic HBV infection, disrupting intrahepatic DC recruitment and HBV‐specific CD8+ T‐cell differentiation and function. Targeting the ADORA2A/NFκB/CCL5 axis restores antiviral immunity and facilitates HBV clearance.
Ailu Yang, Yucan Wang, Yating Yu, Jing Wu, Cuiping Bao, Zixuan Wang, Qiuju Han, Zhigang Tian, Jian Zhang, Huajun Zhao   +9 more
wiley   +1 more source

Advancements in Syphilis Vaccine Development. [PDF]

Sex Transm Dis
Giacani L, Cameron CE, Zhao F, Caimano MJ, Radolf JD.   +4 more
europepmc   +1 more source

Integrated Single‐Cell and TCR Profiling Reveals Protection‐Associated CD8+ T Cell Subsets Linked to Viral Control in PRRSV

Advanced Science, EarlyView.
PRRSV vaccine‐mediated protection is associated with clonally expanded cytotoxic CD8+ T cell subsets driven by viral structural proteins and supported by innate TLR4/TLR8 signaling and CD4+ T cell help, whereas non‐protective responses are characterized by dysfunctional exhausted‐like CD8+ T cells linked to poor viral control.
Can Kong, Siang Chen, Maolin Li, Meng Wang, Hailin Zhang, Bolun Zhou, Zhenhua Xie, Chen Wang, Peng Gao, Jianjun Luo, Hanchun Yang, Runsheng Chen, Dongdong Zhang, Jie Li, Jun Han   +14 more
wiley   +1 more source

Artificial intelligence for translational personalized neoantigen cancer vaccine development. [PDF]

J Biomed Sci
Wei CY, Lin HC, Wu CJ, Kuo CN, Chang CM, Chou WH, Chou SP, Feng SH, Huang WC, Jiang S, Fairfax BP, Lee KY, Chang WC.   +12 more
europepmc   +1 more source

The Application of Single-Cell Technologies for Vaccine Development Against Viral Infections

The development of vaccines against viral infections has advanced rapidly over the past century, propelled by innovations in laboratory and molecular technologies.
Isabel O. Vanderzee, Hong Nhi Nguyen, Fei Wen   +2 more
core   +1 more source

Nanovesicles With Mechanically Induced Adjuvanticity for Robust Melanoma Vaccination Toward Tumor‐Associated Macrophages

Advanced Science, EarlyView.
Rigidity‐tunable nanovesicle (P‐Pm) with mechanically induced adjuvanticity toward tumor‐associated macrophages (TAMs) was designed to engineer R848/gp100 antigen ‐loaded nanovaccine (P@Rg‐Pm), which achieved outstanding anti‐tumor outcomes in both therapeutic and preventive model of B16‐F10 melanoma.
Bangyue Luo, Liyan Qiu
wiley   +1 more source

Encephalitic Alphaviruses: Epidemiology, Pathogenesis and Vaccine Development. [PDF]

Vaccines (Basel)
Kisra N, de Zeeuw Z, Eustace G, Gladman R, Ji Y, Pagliari S, Kim YC.   +6 more
europepmc   +1 more source

Malaria serology for surveillance, insights into immunity, and vaccine development. [PDF]

Infect Immun
Lim PS, Bernal J, Karunarathne J, Longley RJ.   +3 more
europepmc   +1 more source

BCG HSP70 Reprograms Macrophages via Central Trained Immunity to Suppress Prostate Cancer

Advanced Science, EarlyView.
BCG‐derived HSP70 (Dnak) safely induces central trained immunity via epigenetic, metabolic, and O‐GlcNAcylation reprogramming of bone marrow progenitors, driving tumor‐associated macrophages toward an M1‐like phenotype to suppress prostate cancer. ABSTRACT Trained immunity offers a promising yet clinically challenging strategy for cancer immunotherapy,
Peng Liu, Kangkang Liu, Keruo Wang, Heyang Guan, Jiaming Fan, Taipeng Li, Jiaru Hao, Zeyuan Wang, Yongchao Yan, Jiatong Chen, Yuan Ma, Yang Yang, Yuanjie Niu   +12 more
wiley   +1 more source